每经头条（nbdtoutiao）——独家对话特斯拉FSD跨美第一人：4400公里"零接管"，手没碰过方向盘！作 为激光雷达销售员，他为何站队马斯克的"纯视觉"？ （记者 张明双） 每经AI快讯，富祥药业1月9日晚间发布公告称，江西富祥药业股份有限公司拟与上海凌凯科技股份有 限公司签署《股权转让协议》，将持有的上海凌富药物研究有限公司39.2%股权（对应公司注册资本 3920万元）以4277万元的价格转让给上海凌凯，本次交易完成后，公司将不再持有上海凌富股权。 ...

Core Viewpoint - The company plans to transfer 39.20% of its stake in Shanghai Lingfu Pharmaceutical Research Co., Ltd. to Shanghai Lingkai Technology Co., Ltd. for a price of 42.77 million yuan, aiming to enhance liquidity and reduce investment risks [1] Group 1 - The company will no longer hold any equity in Shanghai Lingfu after the transaction [1] - The purpose of the share transfer is to achieve capital recovery and concentrate resources to strengthen core competitiveness in its main business [1] - The company expects to optimize its investment structure to further enhance asset liquidity and overall risk resistance [1]

Group 1 - The core viewpoint of the article is to introduce the CSI Technology Advantage Growth 50 Strategy Index, which aims to provide investors with multi-factor strategy investment targets based on the technology sector [1] - The index selects stocks from the technology industry based on factors such as growth, innovation, value, low volatility, and quality, focusing on companies with high trading volumes [1] - The index is rebalanced quarterly, with a maximum weight of 10% and a minimum of 0.1% for individual stocks [2] Group 2 - The top ten constituent stocks of the index include leading companies in various technology sectors, with a combined weight of 30.93% for the top ten stocks [2][3] - The index is heavily weighted towards large-cap stocks, with 31 constituents having a market capitalization exceeding 100 billion yuan [3][4] - The index shows a significant focus on the electronics industry, while also maintaining weights in telecommunications, computing, and pharmaceuticals [3] Group 3 - The article presents the performance of various factors within the sample space, indicating that growth, consensus expectations, and low volatility factors exhibit strong stock selection effects [20] - The analysis includes a comparison of the Technology 50 Strategy Index with other technology and innovation indices, highlighting its historical performance and annual returns [20][22] - The Technology 50 Strategy Index has a cumulative return of 97.26% over the backtesting period, ranking third among six technology indices [23] Group 4 - The expected revenue growth for the Technology 50 Strategy Index in 2026 is projected at 33.65%, outperforming other technology indices [25][29] - The index employs 11 factors for stock selection, providing a comprehensive evaluation compared to other indices that focus on fewer factors [31][32] - The article emphasizes the importance of analyst consensus expectations as a forward-looking indicator for company performance [31]

证券之星消息，1月9日化学制药板块较上一交易日上涨1.77%，前沿生物领涨。当日上证指数报收于 4120.43，上涨0.92%。深证成指报收于14120.15，上涨1.15%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688221 | 前沿生物 | 28.15 | 19.99% | 30.53万 | | 7.86亿 | | 688091 | 上海谊众 | 60.84 | 17.29% | 11.94万 | | 6.88亿 | | 688658 | 悦康药业 | 31.79 | 17.13% | 20.04万 | | 5.86亿 | | 600513 | 联环药业 | 21.11 | 10.01% | 1 30.53万 | | 6.20亿 | | 601089 | 福元医药 | 30.27 | 9.99% | 10.86万 | | 3.10亿 | | 688356 | 键凯科技 | 101.00 | 8.57% | 3.59万 | | 3.51亿 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——独家对话特斯拉FSD跨美第一人：4400公里"零接管"，手没碰过方向盘！作 为激光雷达销售员，他为何站队马斯克的"纯视觉"？ 每经AI快讯，普洛药业1月9日晚间发布公告称，截至2026年1月8日，本次回购方案已实施完毕。公司 实际回购时间区间为2025年11月28日至2026年1月8日，公司通过股票回购专用证券账户以集中竞价交易 方式累计回购公司股份2209万股，占公司目前总股本的1.91%，最高成交价16.85元/股，最低成交价 15.71元/股，成交总金额为人民币约3.6亿元回购资金总额为人民币约3.6亿元。 ...

Core Viewpoint - The ChiNext 50 Index experienced a significant increase on January 9, closing at 1475.97 points with a rise of 1.43%, reflecting a strong market performance despite initial fluctuations [1]. Group 1: Market Performance - The ChiNext Composite Index rose by 2.08% to close at 1803.4 points, with a total trading volume of approximately 327.2 billion yuan [1]. - The average increase for the 600 stocks on the ChiNext board was 2.04%, with an average turnover rate of 4.48% and a total trading volume of 327.2 billion yuan [1]. - The index showed a volatility of 2.73% during the trading session, indicating active trading [1]. Group 2: Sector Performance - Communication equipment and chemical pharmaceutical stocks demonstrated strong performance, while semiconductor and healthcare stocks faced declines [1]. - Individual stock performances included Zhenyou Technology, Xinke Yidong, and Qianyan Biology reaching the daily limit up, while Shengbang Security saw a decline of 7.18%, marking the largest drop [1]. Group 3: Trading Details - Cambrian Technology led in trading volume with 14.9 billion yuan, while ST Yifei had the lowest trading volume at 1.259 million yuan [2]. - Strong Yi Co. had the highest turnover rate at 39.07%, while Longteng Optoelectronics recorded the lowest at 0.28% [2].

Group 1 - The core viewpoint of the report is that the CSI Technology Advantage Growth 50 Strategy Index (referred to as Technology 50 Strategy) utilizes multiple factors such as growth, innovation, value, low volatility, and quality to select and weight stocks from the technology sector, aiming to provide investors with a multi-factor strategy investment target based on the technology industry [1][7][11] - As of December 31, 2025, the top ten constituent stocks of the Technology 50 Strategy Index are primarily leading companies across various technology sub-sectors, with the top five stocks accounting for 17.63% and the top ten stocks accounting for 30.93% of the index's total weight [1][10][11] - The index is biased towards large-cap stocks, with 31 constituents having a market capitalization exceeding 100 billion yuan, while only 2 constituents have a market capitalization below 10 billion yuan [1][11] Group 2 - The report compares the Technology 50 Strategy Index with other representative technology and innovation indices, noting that the Technology 50 Strategy Index achieved an annualized return of 11.96% from January 1, 2020, to December 31, 2025, ranking third among six technology and innovation indices [1][57][60] - The Technology 50 Strategy Index shows lower volatility in revenue growth compared to other indices, with a projected revenue growth rate of 33.65% for 2026, which is higher than that of the other five technology and innovation indices [1][61][62] - The selection of constituent stocks for the Technology 50 Strategy Index incorporates 11 factors, providing a more comprehensive evaluation compared to other indices that focus on fewer factors [1][67][68]

Group 1 - Bid Pharma's stock increased by 5.07% to 68.44 CNY per share, with a trading volume of 68.3753 million CNY and a turnover rate of 2.38%, resulting in a total market capitalization of 6.22 billion CNY [1] - The company, established on April 27, 2007, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Morgan Stanley Fund has a significant holding in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund reducing its holdings by 15,300 shares to 53,000 shares, representing 6.6% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 29.6292 million CNY and has achieved a year-to-date return of 8.64%, ranking 427 out of 8,827 in its category, and a one-year return of 26.74%, ranking 4,492 out of 8,084 [2]

Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical has experienced a significant stock price increase, rising 7.58% on January 9, with a total market value of 11.946 billion yuan and a cumulative increase of 9.94% over four consecutive days [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The company's main business revenue composition includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position, having reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which is 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100), established on September 29, 2016, has a current scale of 76.63 billion yuan, with a year-to-date return of 4.96% and a one-year return of 42.74% [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a tenure of 7 years and 65 days, with a total asset scale of 122.76 billion yuan, achieving a best return of 208.53% and a worst return of -15.93% during the tenure [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、回购股份方案的基本情况 烟台东诚药业集团股份有限公司（以下简称"公司"）于2025年12月31日召开第六届董事会第十七次会 议，审议通过了《关于以集中竞价方式回购股份方案的议案》，同意公司使用自有资金及自筹资金以集 中竞价交易的方式回购公司股份，回购的股份将用于实施股权激励和/或员工持股计划。回购价格不超 过人民币18.00元/股（含），回购资金总额不低于人民币10,000万元（含），不超过人民币20,000万元 （含），回购期限自公司董事会审议通过回购股份方案之日起不超过12个月。具体内容详见公司于2026 年1月5日、2026年1月6日在巨潮资讯网（www.cninfo.com.cn）披露的《关于以集中竞价方式回购股份 方案的公告》、《回购报告书》。 二、取得金融机构股票回购专项贷款承诺函的情况 近日，公司取得招商银行股份有限公司烟台分行出具的《贷款承诺函》，承诺为公司本次回购股份专项 贷款融资提供支持，主要内容如下： 1、贷款银行：招商银行股份有限公司烟 ...